BCD-054 (sampeginterferon beta-1a) News

||||||||||  BCD-054 (sampeginterferon beta-1a) / Biocad
Trial completion:  Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis (clinicaltrials.gov) -  Sep 8, 2021
P2/3, N=399, Completed,  Sponsor: Biocad
Active, not recruiting --> Completed

|||||||||| BCD-054 (PEG-interferon Î²-1a biosimilar) / Biocad
Journal: The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis (Pubmed Central) - Feb 21, 2020
Manifestations of flu-like syndrome that is expected for interferon treatment were observed with the same incidence in all the active treatment groups. Its severity, duration or the need for symptomatic treatment did not appear to depend on the type of interferon used.

||||||||||  BCD-054 (sampeginterferon beta-1a) / Biocad
Enrollment closed:  Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis (clinicaltrials.gov) -  Jul 17, 2018
P2/3, N=399, Active, not recruiting,  Sponsor: Biocad
Its severity, duration or the need for symptomatic treatment did not appear to depend on the type of interferon used. Recruiting --> Active, not recruiting

||||||||||  BCD-054 (sampeginterferon beta-1a) / Biocad
Enrollment open, Phase classification, Enrollment change, Trial initiation date, Trial primary completion date:  Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis (clinicaltrials.gov) -  Sep 11, 2017
P2/3, N=399, Recruiting,  Sponsor: Biocad
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=165 --> 399 | Initiation date: Aug 2016 --> Aug 2017 | Trial primary completion date: Aug 2017 --> Jan 2020

||||||||||  BCD-054 (sampeginterferon beta-1a) / Biocad
Enrollment change:  Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif (clinicaltrials.gov) -  Apr 10, 2017
P1, N=60, Completed,  Sponsor: Biocad
Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3 | N=165 --> 399 | Initiation date: Aug 2016 --> Aug 2017 | Trial primary completion date: Aug 2017 --> Jan 2020 N=36 --> 60

||||||||||  BCD-054 (sampeginterferon beta-1a) / Biocad
Trial completion, Trial primary completion date:  Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif (clinicaltrials.gov) -  Jan 15, 2016
P1, N=36, Completed,  Sponsor: Biocad
N=36 --> 60 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Oct 2015

||||||||||  BCD-054 (sampeginterferon beta-1a) / Biocad
New P1 trial:  Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif (clinicaltrials.gov) -  Feb 10, 2015
P1, N=36, Active, not recruiting,  Sponsor: Biocad



	Diseases Companies Products Productz Mechanisms of Action Sites